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Abstract: A 69-year-old woman with a history of cervical cancer was admitted to our hos-
pital for further investigation of abnormal shadows on her chest roentgenogram. Histologic 
examination of transbronchial lung biopsy specimens revealed epithelioid cell granuloma, and 
Mycobacterium intracellulare was detected in the bronchial lavage fluid. The plasma level of 
(1→3)-beta-d-glucan was very high, and this elevated level was attributed to administration 
of sizofiran for treatment of cervical cancer 18 years previously. Therefore, in patients with 
cervical cancer, it is important to confirm whether or not sizofiran has been administered before 
measuring (1→3)-beta-d-glucan levels.
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Introduction
(1→3)-beta-d-glucan is a characteristic cell wall component of almost all fungi. The 
measurement of the plasma concentration of this glucan is clinically useful when 
screening for invasive fungal infections or fungal febrile episodes.1 In addition, this 
glucan is known to stimulate humoral and cell mediated immunity in humans, and has 
antitumor effects.2 High plasma concentrations of (1→3)-beta-d-glucan may occur 
even in the absence of a fungal infection because of the administration of sizofiran, 
an antitumor (1→3)-beta-d-glucan preparation (SPG; Kaken Pharmaceuticals, 
Tokyo, Japan). We report an extremely rare case of a patient with elevated plasma 
concentrations of (1→3)-beta-d-glucan 18 years after she was treated with sizofiran 
for cervical cancer.
Case report
A 69-year-old woman was admitted to our hospital in November 2007 for further 
examination of abnormal shadows in both lungs. She was a nonsmoker and had no 
history of occupational exposure. She had undergone hysterectomy in 1990 and was 
administered SPG for six months thereafter. Physical examination revealed that she 
had no skin lesions or neurologic abnormalities. There was no peripheral lymphade-
nopathy in the cervical, axillary, or inguinal region. Fine crackles were audible in the 
middle lung fields bilaterally.
The white blood cell count was 6.2 × 109/L, with 56.6% neutrophils, 34.3% 
lymphocytes, 5.2% monocytes, 3.2% eosinophils, and 0.7% basophils. The level of 
C-reactive protein was normal. Her fasting blood glucose level was 149 mg/dL and 
HbA1c was 6.8%. The serum concentration of immunoglobulin G (IgG) was elevated International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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to 2034 mg/dL (normal, 837–1825 mg/dL), and the serum 
IgM and IgA levels were within the normal range. The level 
of (1→3)-beta-d-glucan was elevated to 260 pg/mL (cutoff 
value, 11 pg/mL) and the plasma endotoxin level was normal. 
Aspergillus antigens (Platelia® Aspergillus EIA; Bio-Rad, 
Marnes-la-Coquette, France) and Candida antigens (Cand-
Tec; Ramco Laboratories, Inc., Houston, TX.) were absent. 
There was no liver and kidney dysfunction. A chest roent-
genogram showed infiltrative shadows in both lungs (Fig-
ure 1). Chest computed tomography revealed centrilobular 
nodules and patchy infiltrative shadows. Bronchiectasis was 
observed in the upper lobes of both lungs and in the middle 
lobe of the right lung (Figure 2). There was no radiographic 
evidence of infection, purulence, or tumors of the abdominal 
or pelvic organs. The areas of intense fluorodeoxyglucose 
activity detected by 18FDG-positron emission tomography 
coincided with the infiltrative shadows detected by computed 
tomography. Histologic examination of transbronchial lung 
biopsy specimens obtained from the right upper lobe revealed 
epithelioid cell granuloma (Figure 3). Mycobacterium 
intracellulare was detected in the bronchial lavage fluid, but 
Aspergillus spp, Candida spp, and Pneumocystis jiroveci 
were not detected. There was no evidence of systemic fungal 
infection in this patient. Therefore, the patient was diagnosed 
with pulmonary M. intracellulare infection. However, the 
cause of the high plasma concentration of (1→3)-beta-
d-glucan remained unknown. Because the possibility of 
deep-seated mycosis could not be ruled out, the patient was 
treated with oral voriconazole for three months. However, 
the plasma concentration of (1→3)-beta-d-glucan remained 
high; by February 2009, it had increased from 160 pg/mL 
to 410 pg/mL (Figure 4). Because it was unlikely that any 
other factor was responsible, we concluded that the high 
(1→3)-beta-d-glucan level was caused by intramuscular 
injections of 40 mg SPG every week for six months, which 
had been administered for the treatment of cervical cancer 
18 years previously.
Discussion
The plasma concentration of (1→3)-beta-d-glucan, a 
characteristic cell wall component of almost all fungi and 
absent in bacteria, is widely used in Japan as an indicator 
of fungal infection. In 2004, the United States Food and 
Drug Administration recognized that measurement of 
this glucan is useful for the detection of fungal infection.  Figure 1 Chest roentogenogram showing infiltrative shadows in both lungs.
Figure 2 Chest computed tomography showing centrilobular nodules and patchy 
infiltrative shadows and bronchiectasis in the upper lobes of both lungs and the 
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Factor G in the lysate from the Japanese horseshoe crab 
(Tachypleus tridentatus) reacts with (1→3)-beta-d-glucan 
[3]. Obayashi et al reported that the determination of plasma 
(1→3)-beta-d-glucan concentration for the detection of 
fungal infection with a cutoff value of 20 pg/mL has a 
sensitivity of 90% and a   specificity of 100%.1 In Japan, 
three test kits are currently available for the measurement 
of plasma glucan levels, ie, the FUNGITEC G Test MK 
(FUNGITEC-MK),   beta-Glucan Test Wako (Wako), and 
beta-Glucan Test Maruha (Maruha). The FUNGITEC-MK 
kit, which involves alkaline   pretreatment of the sample 
before measurement, is widely used in Japan because it is 
highly sensitive and enables easy handling of many samples. 
In our hospital, we measure glucan   levels using the Wako 
kit, which shows an overall agreement rate of nearly 90% 
with the FUNGITEC-MK kit for fungal infection.4 However, 
in cases where (1→3)-beta-d-glucan preparations, such as 
SPG and lentinan, have been administered, alkaline pretreat-
ment of the sample (FUNGITEC-MK kit) yields drastically 
higher beta-d-glucan values than the values obtained by 
dilution and heat pretreatment (Wako and Maruha kits).5 
SPG and lentinan have a triple helical conformation that 
is denatured into a single helical structure under alkaline 
conditions.6,7 Most of the (1→3)-beta-d-glucan in the blood 
of patients with deep-seated mycosis is in the single heli-
cal conformation, which reacts more strongly with factor 
G than the triple helical conformation of beta-d-glucan.5 
In December 2008, the level of (1→3)-beta-d-glucan in 
our patient was found to be 3240 pg/mL (cutoff value, 
20 pg/mL) with the FUNGITEC-MK kit and 124 pg/mL 
(cutoff value, 11pg/mL) with the Maruha kit, whereas the 
glucan level was found to be 268 pg/mL with the Wako kit. 
These results suggested that the administered SPG remained 
in the triple helical conformation, and reacted strongly with 
factor G after alkaline treatment.
Some clinical conditions interfere with the results 
obtained using the Wako kit. False positive reactions have 
been reported in patients receiving human immunoglobulin 
products, which contain substances that react with factor 
G.8 These substances include drugs containing (1→3)-beta-
d-glucan, for example, lentinan and SPG,9,10 the cellulose 
membrane used for hemodialysis,11 and glucan-containing 
gauze used in surgery.12 However, in the case of our patient, 
there was no history of the use of glucan-containing gauze, 
intake of Chinese medicines,13 supplements, over the counter 
medicines for intestinal disorders containing (1→3)-beta-d-
glucan, or administration of blood products, such as albumin 
and globulin.
Lentinan is clinically used as a biologic response 
modifier in the treatment of gastric cancer,9 and SPG is 
used in combination with radiotherapy to improve the 
local response to radiation treatment for cervical cancer.10 
SPG is isolated from culture media in which the basidi-
omycete Schizophyllum commune Fries is grown. It is a 
true glucan (molecular weight approximately 450,000) 
consisting of repeating units of beta-1,3-d-glycopyranosyl 
residues.14
It has been reported that SPG, upon entry into the body, 
is transported to the liver, spleen, and mesenteric lymph 
nodes almost immediately, and its concentration in the blood 
decreases.15 In rats, SPG present in the liver is degraded over 
a period of six months to SPG-like substances, the molecular 
weight of which is lower than that of SPG. Furthermore, SPG 
in the spleen and mesenteric lymph nodes is metabolized at a 
Figure 3 Histologic examination of hematoxylin-eosin stained transbronchial lung 
biopsy specimens obtained from the right upper lobe revealed caseous necrosis with 
lymphocytes, epithelioid granuloma, and Langhans’ giant cells.
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Figure 4 Plasma concentration of beta-D-glucan between November 2007 and 
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much slower rate than in the liver. Finally, SPG is excreted in 
the urine, mainly in the form of metabolites with a molecular 
weight , 10000.16 Hase et al studied the clearance of SPG in 
humans, and found that 30 days after a single intramuscular 
injection of 20 or 40 mg SPG, the blood SPG concentration 
was in the order of tens of nanograms per milliliter.17 Ishi-
zuka et al reported that lentinan (total dose 400 mg) and 
SPG (total dose 280 mg) can be detected in the body at three 
years and 350 days, respectively, after the last intramuscular 
injection.5 The biologic half life of (1→3)-beta-d-glucan in 
humans remains unknown. However, from these reports, 
it can be concluded that the administration of larger doses 
of SPG results in elevation of the plasma concentration of 
(1→3)-beta-d-glucan for longer periods of time.
Our patient was diagnosed with Mycobacterium 
avium complex pulmonary disease. The specificities of 
Cand-Tec and Platelia® Aspergillus EIA used to detect 
fungal infection were 76.9% and 87.5%, respectively, 
while their respective sensitivities were 93.9% and 
78.6%.18,19 However, deep-seated mycosis cannot be 
ruled out only on the basis of laboratory data obtained 
using these kits. In our patient, there was no evidence 
of fungal infection, including clinical symptoms, 
radiographic findings, and laboratory data, except for 
the elevated plasma concentration of (1→3)-beta-d-
glucan. Moreover, oral administration of voriconazole, 
an antifungal agent that acts against a wide variety of 
yeasts and molds,20 for three months did not decrease 
the plasma (1→3)-beta-d-glucan concentration. We 
concluded that intramuscular administration of SPG 
for treatment of cervical cancer 18 years previously 
had caused the increased beta-d-glucan levels. Thus 
far, there have been no reports of long-term elevation 
of blood (1→3)-beta-d-glucan concentrations. The 
maximum blood concentration of (1→3)-beta-d-glucan 
in patients with deep-seated mycosis is in the order of 
several nanograms per milliliter. Thus, we estimated 
that in our patient, the total amount of (1→3)-beta-d-
glucan in circulating blood would be in the order of 
micrograms.5 The cause of the high level of (1→3)-
beta-d-glucan in our patient may have been continuous 
administration of SPG for long periods of time, result-
ing in the accumulation of hundreds of milligrams of 
(1→3)-beta-d-glucan.
(1→3)-beta-d-glucan remains in the peripheral blood 
for many years and interferes with blood (1→3)-beta-d-
glucan measurement. Therefore, in patients with cervical 
cancer, it is important to confirm whether or not SPG has 
been previously administered before measuring (1→3)-
beta-d-glucan levels.
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